How Has Pfizer’s Story Changed?

Pfizer’s revenue over the past twelve months was 0.2% lower than a year earlier. When sales are flat, look at what management leads with on earnings calls to see where it expects growth. Since early 2025, Pfizer’s management has changed what it leads with. It used to lead with the work of absorbing a company it had bought. It now leads with drugs it has not launched. What was that deal?

Seagen Was The Deal

Pfizer (PFE) bought Seagen to build up its cancer drug business. Folding a purchased company into your own is called integration. It means joining two sets of sales teams, research and products into one. Until that work is done, a buyer cannot tell whether the purchase is paying off.

Pfizer led with Seagen on the fiscal Q4 2024 call, held in February 2025. Management said it had “successfully integrated the Seagen business” and spoke of building one of the industry’s best cancer drug companies. Pfizer had spent heavily on Seagen and built its cancer plans around that purchase.

Management still credits Seagen for its cancer business, but it no longer leads with the integration work. On the fiscal Q4 2025 call, in February 2026, the integration came up in a question. That was a year after Pfizer reported the work done.

What Does Pfizer Lead With Now?

Pfizer now leads with plans that have not produced sales yet. On the fiscal Q2 2026 call in August 2026, one lead topic was obesity drugs. Another was using artificial intelligence to speed up drug research. A third was a growth aim that management calls risk-adjusted. The aim is for revenue to grow at a high single-digit average yearly rate from the end of 2028 through the end of 2033.

Pfizer’s obesity drug berobenatide is still in trials, and management is targeting a first approval in 2028. Pfizer is already paying for that work. Research spending rose 12% in fiscal Q2 2026 on management’s adjusted, operational measure. Most of the increase went to cancer and obesity drug candidates.

The drugs that came with Seagen are counted in a group Pfizer calls launched and acquired products. That group brought in $3.2 billion in the same quarter. Pfizer’s total revenue was $15 billion, so the group is about a fifth of the company. On management’s operational measure, the group grew 18%. Management said one-time items a year earlier held that rate down. Pfizer as a whole grew 1% on the same measure, or 5% excluding COVID products.

Is Pfizer’s Changed Story Good Or Bad For Holders?

It is reassuring on the Seagen drugs already on sale and less so on what management leads with now. Management stopped leading with the integration after reporting it done, and the drugs are selling. Seagen’s U.S. drug sales grew 21% in fiscal Q2 2026, excluding a one-time boost a year earlier when buyers stocked up.

The concern is that the new topics will not show up in Pfizer’s sales for years. The obesity drug’s first approval is targeted for 2028. The growth aim starts at the end of that year.

In the meantime, Pfizer is not guiding for growth. It raised its 2026 revenue guidance on the latest call, to a range of $60.5 billion to $62.5 billion. The top of that range is still below fiscal 2025 revenue of $62.6 billion.

Trials can also fail. In June 2026, a cancer drug candidate missed its main goal in a late-stage lung cancer trial. Pfizer cut the value of its assets by $4.3 billion in fiscal Q2 2026, mostly because of that result.

The drugs Pfizer bought and launched are doing their part, growing 18% on management’s operational measure in the latest quarter. The risk is that the drugs meant to follow them are still years from sale. Pfizer’s next report covers fiscal Q3 2026.

Listen for whether management still targets a first approval for the obesity drug in 2028. Then look at launched and acquired products.  Management said one-time items a year earlier held its 18% growth down, and figure was 27% without them. Compare the next figure with both rates. A drop well below 27% on the same basis would be the first sign that those products are slowing before the obesity drug arrives.

Does This Mean You Should Act On PFE?

Our purpose is to inform you with unique data so you make the right investment decisions. That said, betting on a single stock is always risky, no matter which direction you choose.

There is a smarter approach. Since its inception, the Trefis High Quality (HQ) Portfolio has returned 105%, beating the benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. And it did so without taking the concentrated risk that comes with do-it-yourself stock picking. If that is how you want to invest, the HQ Portfolio is the place to start.